Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 7/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014517 | 0.84 | ALDH1A1 (0.49) | JAK2JAK1TYK2JAK3SCN9A | |
| SCHEMBL12424613 | 0.82 | LMNA (0.41) | JAK2JAK1TYK2JAK3SCN9A | |
| SCHEMBL12384431 | 0.80 | SCN9A (0.43) | JAK2JAK1TYK2JAK3SCN9A | |
| SCHEMBL18933374 | 0.77 | JAK2 (0.42) | JAK2JAK1TYK2JAK3SCN9A | |
| SCHEMBL15014645 | 0.75 | LMNA (0.55) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL15698569 | 0.75 | SMN1; SMN2 (0.45) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL12424465 | 0.72 | SCN9A (0.41) | SCN9ATLR9TLR8TLR7KDM4E | |
| SCHEMBL12425852 | 0.72 | MAPT (0.42) | TLR9TLR8TLR7KDM4EMAPT | |
| SCHEMBL13512585 | 0.72 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12425853 | 0.71 | HRH3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK2 122/4885JAK1 434/4885TYK2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.